Logo

Transgenomic Inks Blue Cross and Blue Shield Contract

Dec 14, 2013 | staff reporter

NEW YORK (GenomeWeb News) – Transgenomic said today that it has expanded a national contractual agreement with the Blue Cross and Blue Shield Association.

The Omaha, Neb.-based molecular diagnostics and pharmacogenomics services firm said in a filing with the US Securities and Exchange Commission that the new agreement has a term of five years. Under the contract, Blue Plans affiliates have access to "competitive pricing" for Transgenomic's tests and services.

The firm didn't provide any additional details of the contract.

Transgenomic offers genetic analysis kits for a variety of mutations, including BRAF, KRAS, and NRAS. The kits feature the company's Ice-Cold-PCR technology.

in Friday afternoon trade on the OTC Market shares of Transgenomic were up 14 percent at $.48.

Filed under

PCR
Diagnostics
Reimbursement News
Molecular Diagnostics
Precipio
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.